Is there an optimal management for localized prostate cancer?
Jaspreet Singh , Edouard J Trabulsi, Leonard G GomellaDepartment of Urology Kimmel Cancer Center Thomas Jefferson University Philadelphia, PA, USAAbstract: Widespread screening with prostate-specific antigen (PSA) has led to a significant increase in the detection of early stage, clinically localize...
Guardado en:
Autores principales: | Jaspreet Singh, Edouard J Trabulsi, Leonard G Gomella |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/93a5d75912924df8be875260bb5326b3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller CJ, et al.
Publicado: (2012) -
Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
por: Caffo O, et al.
Publicado: (2016) -
Critical appraisal of cabazitaxel in the management of advanced prostate cancer
por: Sumanta Kumar Pal, et al.
Publicado: (2010) -
Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
por: Rajni Sethi, et al.
Publicado: (2009) -
Serum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinical decision-making
por: Nnabugwu II, et al.
Publicado: (2014)